Figure 6. MVA-TWIST/TRICOM administration reduces the formation of lung metastases when treatment is initiated up to 15 days post-tumor implantation.

BALB/c mice (n = 15/group) were implanted s.c. with 5 × 10⁴ 4T1 cells. Graphs show primary tumor growth in mice treated with A. no treatment, B. MVA-TWIST/TRICOM beginning 7 days post-tumor implantation or C. MVA-TWIST/TRICOM beginning 15 days post-tumor implantation. Vaccinations are indicated by arrows. Inserts: Average tumor growth per group compared to group receiving no treatment. Enumeration of clonogenic metastatic cells, obtained when the group average tumor volume reached 1000mm³, in the lungs of mice treated with D. no treatment, E. MVA-TWIST/TRICOM beginning on day 7 post-tumor implantation or F. MVA-TWIST/TRICOM beginning on day 15 post-tumor implantation. Tumor dimensions were measured weekly. Clonogenic metastatic cells were determined as in previous experiment. Error bars indicate mean ± S.E.M. Statistical analyses were done by Student’s t-test, * = P < 0.01 vs. no treatment. Data are representative of two independent experiments.